PODD Insulet Corporation
Company Analysis
Latest News
Insulet Omnipod 6 boosts glucose control in pivotal STRIVE trial
Insulet announced clinical results for its next-generation tubeless insulin delivery systems at the American Diabetes Association's 86th Scientific...
🟢 Insulet Corporation is trading 5.2% up today on Omnipod 5 enhancements and Abbott sensor integration
Insulet Corporation is trading 5.2% up at $153.99 following the U.S. rollout of significant enhancements to its Omnipod 5 automated insulin delivery system. •...
🟢 Insulet Corporation is trading 4.5% up today on Omnipod 5 upgrade and Abbott sensor integration
Insulet Corporation is trading 4.5% up today at $152.93 after investors reacted positively to the U.S. rollout of enhancements for the Omnipod 5 insulin...
🟢 Insulet Corporation is trading 4.2% up today on the U.S. rollout of Omnipod 5 upgrades and Libre 3 compatibility
Insulet Corporation is trading 4.21% up now at $149.34 as the company begins the U.S. rollout of major upgrades to its Omnipod 5 Automated Insulin Delivery...
Insulet Upgrades Omnipod 5, Adding Abbott FreeStyle Libre 3 Compatibility
Insulet Corporation has initiated the U.S. rollout of significant enhancements to its Omnipod 5 Automated Insulin Delivery (AID) System. The FDA cleared the...
🔴 Insulet Corporation is trading 4.1% down today following a voluntary device correction for its Omnipod pods
Insulet Corporation is trading 4.1% down today at $142.00 after the company initiated a voluntary medical device correction for certain lots of its Omnipod...
Insulet loses $59M trade secret award, filed lawsuit too late
A U.S. appeals court overturned a $59.4 million verdict for medical device maker Insulet against South Korean competitor EOFlow. The U.S. Court of Appeals for...
🔴 PODD is trading 6.7% down today after Omnipod recall and $50 million financial impact
PODD is trading 6.7% down at $143.52 following a voluntary recall of certain Omnipod insulin delivery system lots and an estimated $50 million financial...
🔴 PODD is trading 5.1% down today on Omnipod recall and $50M financial impact
Insulet (PODD) is trading 5.1% down at $146.02 in pre-market following a voluntary correction and recall of certain lots of its Omnipod insulin delivery...
Insulet's Omnipod Recall Rattles Investors — But Can the Company Really Absorb a $50 Million Hit Without Missing a Beat?
Shares of Insulet Corporation plunged 8.4% after hours to $140.89, erasing a week of steady gains, after the insulin-pump maker disclosed a voluntary...
Insulet Announces Voluntary Omnipod Correction, Expects Up to $50M in Costs
Insulet Corporation announced a voluntary Medical Device Correction for specific lots of its Omnipod products due to a manufacturing issue that could lead to...